Possibilities of Use MRI-Guided Laser Interstitial Thermal Therapy in Medically Intractable Tremor

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Hospitalier Universitaire, Amiens

About this trial

Medically intractable tremors are a common difficult clinical situation. Deep brain stimulation decreases Parkinson's disease tremor and essential tremor, but not all patients are candidates from a diagnostic, medical, or social standpoint, prompting the need for alternative surgical strategies. Less invasive lesional brain surgery (thalamotomy) procedures by radio-surgery or MRI-guided focused ultrasound have emerged and have proven to be effective in these third-line indications. Recently, a new technology has emerged allowing the performance of minimally invasive lesion surgeries by MRI-Guided Laser Interstitial Thermal Therapy (MRIg-LITT). MRIg-LITT has been shown to be effective and safe in management of epilepsies and brain tumors. However, no study has evaluated MRIg-LITT for performing thalamotomy in medically intractable tremor.In a pilot study, the investigators propose to evaluate the effect and safety of unilateral thalamotomy by MRIg-LITT in the management of medically intractable tremor of parkinsonian or essential origin.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients 18 years age or older with Parkinson's disease or essential tremor and tremor resistant to medical therapy with a contraindication to deep brain stimulation or refusal deep brain stimulation

Disqualifiers

Contraindication to MRI

Contraindication to general anesthesia

Patient unable to give their free and informed consent because of cognitive or psychiatric disorders

Brain anatomical abnormalities not allowing intervention

Trial design

Design model

Single group

Treatments tested in this trial

  • laser electrode

    Procedure/Surgery

    A laser electrode is implanted surgically in the ventral and inteermediary nucleus of the thalamus (VIM).

Treatment groups

15 Participants
are divided into 1 treatment group
Group A: Parkinson's diseaseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Variation of total body weight from baseline

To assess the impact of UF prescription guided by the ECW/TBWat ratio on weight loss, a comparison of TBW (∆TBW) between the two groups will be conducted. The ∆TBW is the difference between the initial TBW at H0 and the TBW at H72.

Time frame
at 72 hours

Secondary outcomes

1

cumulative fluid balance

Cumulative fluid balance is the difference between fluids administered (intravenous fluids, blood products, enteral nutrition, replacement fluid from RRT) and fluid loss (weight loss from RRT, urine output, blood loss, enteral loss, and losses through drains). It is calculated using the cumulative net UF from RRT and the hospital software (DianeRéa, Bowmedical, version 4.8.11.22887) over the period from H0 to H72.

Time frame
at 72 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Centre Hospitalier Universitaire, Amiens

Lead sponsor

University Hospital, Rouen

Collaborator

University Hospital, Caen

Collaborator

Central Hospital Saint Quentin

Collaborator